TherapeuticsMD Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di TherapeuticsMD.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	23.8%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition

Jul 06

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

Jun 16

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

Mar 14

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

Oct 22

TherapeuticsMD: The Long Road To Profitability

Jul 08

TherapeuticsMD drops 3% despite consensus beating Q1 results

May 06

TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?

Feb 24

TherapeuticsMD: Annovera May Save The Day

Feb 04

TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be

Jan 29

What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?

Jan 27

Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?

Dec 30

TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years

Dec 09

TherapeuticsMD: Q3 Report Reveals Strong Rebound And Bolsters Commercial Outlook

Nov 25

Therapeutics MD EPS beats by $0.01, beats on revenue

Nov 09

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché TherapeuticsMD non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:TXMD - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
9/30/2024	2	-4	-7	-7	N/A
6/30/2024	1	-5	-9	-9	N/A
3/31/2024	1	-6	-15	-15	N/A
12/31/2023	1	-8	-48	-48	N/A
9/30/2023	69	42	-141	-141	N/A
6/30/2023	70	29	-128	-128	N/A
3/31/2023	70	17	-8	-8	N/A
12/31/2022	70	1	-4	-4	N/A
9/30/2022	-64	3	55	57	N/A
6/30/2022	-39	-30	7	9	N/A
3/31/2022	-17	-58	-136	-134	N/A
12/31/2021	3	-79	-145	-143	N/A
9/30/2021	91	-172	-135	-133	N/A
6/30/2021	85	-157	-131	-129	N/A
3/31/2021	72	-166	-160	-159	N/A
12/31/2020	65	-184	-161	-159	N/A
9/30/2020	58	-191	-202	-180	N/A
6/30/2020	63	-190	-195	-172	N/A
3/31/2020	58	-193	-190	-167	N/A
12/31/2019	50	-176	-190	-166	N/A
9/30/2019	39	-166	-147	-143	N/A
6/30/2019	19	-170	-174	-151	N/A
3/31/2019	16	-148	-147	-125	N/A
12/31/2018	16	-133	-128	-107	N/A
9/30/2018	15	-115	-121	-99	N/A
6/30/2018	16	-94	N/A	-82	N/A
3/31/2018	17	-80	N/A	-75	N/A
12/31/2017	17	-77	N/A	-76	N/A
9/30/2017	17	-78	N/A	-71	N/A
6/30/2017	18	-89	N/A	-73	N/A
3/31/2017	18	-90	N/A	-70	N/A
12/31/2016	19	-90	N/A	-69	N/A
9/30/2016	20	-85	N/A	-70	N/A
6/30/2016	20	-79	N/A	-70	N/A
3/31/2016	21	-85	N/A	-79	N/A
12/31/2015	20	-85	N/A	-79	N/A
9/30/2015	19	-84	N/A	-78	N/A
6/30/2015	18	-82	N/A	-71	N/A
3/31/2015	17	-66	N/A	-56	N/A
12/31/2014	15	-54	N/A	-46	N/A
9/30/2014	14	-46	N/A	-35	N/A
6/30/2014	12	-36	N/A	-29	N/A
3/31/2014	10	-31	N/A	-26	N/A
12/31/2013	9	-28	N/A	-21	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista TXMD è superiore al tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di TXMD cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di TXMD cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di TXMD cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di TXMD cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di TXMD è previsto essere elevato tra 3 anni

TherapeuticsMD Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$3.75

Forecast breakeven date pushed back to 2024

Consensus revenue estimates fall by 24%

Forecast breakeven date pushed back to 2024

Recent updates

Third quarter 2024 earnings released: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023)

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD raises $7M in private placement

Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board

TherapeuticsMD appoints interim co-CEOs

TherapeuticsMD, Inc. Appoints Justin Roberts as A Director

Therapeutics MD Q2 Earnings Preview

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

TherapeuticsMD receives $15M equity investment from Rubric Capital

TherapeuticsMD jumps 12% as top investor discloses insider purchase

Essex Woodlands Management, Inc. cancelled the acquisition of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD plunges 42% as merger agreement ends

TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from NASDAQ Biotechnology Index

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

TherapeuticsMD’s Common Stock No Longer Be Listed on Any Public Market Upon Completion of Transaction with EW Healthcare Partners

Essex Woodlands Management, Inc. entered into a definitive merger agreement to acquire TherapeuticsMD, Inc. (NasdaqGS:TXMD) for $93 million.

Consensus forecasts updated

Therapeuticsmd, Inc. Receives U.S. Food and Drug Administration (Fda) Approval for Supplemental New Drug Application (Snda) for Annovera®

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Consensus forecasts updated

Price target decreased to US$3.75

Co-Founder notifies of intention to sell stock

Forecast breakeven date pushed back to 2024

GoodRx Holdings, Inc. (NasdaqGS:GDRX) completed the acquisition of Vitacare Prescription Services, Inc from from TherapeuticsMD, Inc. (NasdaqGS:TXMD) for approximately $160 million.

Co-Founder notifies of intention to sell stock

Consensus revenue estimates fall by 24%

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Robert G. Finizio Notifies TherapeuticsMD, Inc. of His Decision to Resign from the Board of Directors of the Company and as Vice Chair

Independent Director recently bought US$579k worth of stock

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Forecast to breakeven in 2023

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

Executive Vice President of Operations Edward Borkowski has left the company

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Independent Director recently bought US$725k worth of stock

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)

No longer forecast to breakeven

TherapeuticsMD: The Long Road To Profitability

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from Russell 3000E Value Index

TherapeuticsMD, Inc. Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

Co-Founder exercised options and sold US$70k worth of stock

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)

TherapeuticsMD drops 3% despite consensus beating Q1 results

Revenue and earnings beat expectations

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)

TherapeuticsMD, Inc. to Report Q4, 2020 Results on Mar 02, 2021

TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

TherapeuticsMD: Annovera May Save The Day

Price target raised to US$8.00

TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be

What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?

New 90-day high: US$1.61

Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?

TherapeuticsMD, Inc. Announces the Launch of Just Say Vagina to Encourage Women to Speak Clearly and Directly About Their Reproductive Health

TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years

New 90-day low: US$1.21

Price target raised to US$8.20